Navigation Links
Quadruple therapy shows 100 percent SVR for HCV patients previously unresponsive to treatment
Date:4/2/2011

Berlin, Germany, Saturday 02 April 2011: Exciting new data presented today at the International Liver CongressTM 2011 show that quadruple therapy in chronic hepatitis C (HCV) patients suppressed the emergence of resistant variants and resulted in a 100% rate of sustained virological response - undetectable HCV RNA - 12 weeks after treatment (SVR12).1

In the quadruple therapy study, HCV patients were given four drugs in combination; pegylated Interferon-alpha (PegIFN-alpha); ribavirin (RBV); and two different direct-acting antivirals (DAAs) BMS-650032 (an HCV NS3 protease inhibitor) and BMS-790052 (an HCV NS5A replication complex inhibitor).

The current standard of care (SoC) for HCV therapy is PegIFN-alpha plus RBV a dual therapy. The addition of DAAs (currently in phase-III clinical trials) marks the next step in treatment evolution a triple therapy. However, the new data presented today suggests that quadruple therapy could be the next generation of treatment for chronic HCV patients.

Professor Heiner Wedemeyer, EASL'S Secretary General, said: "Quadruple therapy is possibly the future of HCV treatment; this study goes a way to confirming that. While it's expected that the first DAAs and triple therapy will be approved for use later this year, quadruple therapy appears to have a more profound effect on virological response, with less of a resistance problem."

The study may also provide new hope for a growing number of HCV patients who cannot be effectively treated for chronic hepatitis with current treatments.

The Phase-IIa trial looked at a cohort of 21 HCV genotype 1 null responders (patients who have failed to respond to previous treatment), of whom 19 had an unfavourable IL28B genotype, which predisposes HCV patients to treatment failure.

Only about 30% of null responders to PegIFN-alpha/RBV treatment achieve sustained virological response (SVR) when retreated with PegIFN-alpha/RBV plus telaprevir,
'/>"/>

Contact: Travis Taylor
easlpressoffice@cohnwolfe.com
44-784-306-9451
European Association for the Study of the Liver
Source:Eurekalert

Page: 1 2

Related medicine news :

1. Insulin could be Alzheimers therapy
2. Early Brain Therapy May Help Movement in Dystonia Patients
3. New approach to leukemia chemotherapy -- is a cure in sight?
4. Benefits of Radiation Therapy Outweigh Risks of a Second Cancer: Study
5. New Therapy for Enlarged Prostate May Bypass Unpleasant Side Effects
6. For potentially crippling dystonia, earlier deep brain therapy gets better, quicker results
7. Scientists devise targeted therapy strategy for rare form of childhood cancer
8. FDA approves ipilimumab, an immunotherapy, to treat metastatic melanoma
9. Novel immunotherapy drug receives FDA approval for the treatment of metastatic melanoma
10. Interest in Toys May Predict Success of Autism Home Therapy
11. Short Course of Hormone Therapy Boosts Prostate Cancer Survival: Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... August 29, 2014 Glendale Botox ... promotion on Botox throughout the month of September. This special ... of two syringes of Juvederm. Patients can take advantage of ... skin. The Glendale Botox experts will work with patients to ... , What is Botox? , Botox is a ...
(Date:8/29/2014)... The way that parents respond to their infant,s babbling ... suggests. Over six months, researchers observed the interactions ... The sessions were 30 minutes long and happened twice ... the start of the study. When parents listened ... form complex sounds. The babies whose parents responded to ...
(Date:8/29/2014)... 29, 2014 Empty Nest Syndrome ... http://www.blogtalkradio.com/dr-carol-francis/2014/08/29/psychologist-dr-carol-francis-addressing-empty-nest-syndrome .     , Mothers and fathers, who ... marital bliss, prodding, laughing and sweating through parenting, ... this week. Relief and parenting pride intermix ... Dr. Carol Francis as a Clinical ...
(Date:8/29/2014)... TayganPoint Consulting Group, a leading strategic ... time, Inc. Magazine has named the company one of ... on solid revenue growth of over 166% over the ... the list. TayganPoint’s repeat success in this ranking, ... few years, is a demonstration of its strong business ...
(Date:8/29/2014)... CA (PRWEB) August 29, 2014 Fat is ... and bad fat. Brown fat is usually stored in the ... white fat typically reveals itself in overflowing bellies, muffin tops, ... fats occur naturally in many foods and promote better health, ... risks, including elevated bad cholesterol levels and lower good cholesterol ...
Breaking Medicine News(10 mins):Health News:Glenoaks Laser Center is Now Offering a Special Promotion on Botox for the Month of September 2Health News:Encouraging Your Baby's Babbling May Speed Language Development 2Health News:Psychologist Dr. Carol Francis Addressing Empty-Nest Syndrome on Talk Radio Today 2Health News:Psychologist Dr. Carol Francis Addressing Empty-Nest Syndrome on Talk Radio Today 3Health News:Diet Doc Announces Modernized, Interesting and Easy to Follow Diet Plans that Deliver Fast Weight Loss and Teach Patients the Difference Between Good and Bad Fat 2Health News:Diet Doc Announces Modernized, Interesting and Easy to Follow Diet Plans that Deliver Fast Weight Loss and Teach Patients the Difference Between Good and Bad Fat 3
... , FRIDAY, Feb. 18 (HealthDay News) -- Patients with ... radiation treatments have a much lower long-term survival rate than ... the study of patients with squamous cell carcinoma of the ... to smoke were still alive five years after treatment, compared ...
... Scientists at the Children,s Center for Cancer and Blood ... Los Angeles today announced a breakthrough discovery in understanding ... a protein called CD19-ligand (CD19-L) located on the surface ... and destruction of leukemia cells by the immune system. ...
... 18 (HealthDay News) -- Speaking more than one language may ... that bilingual speakers outperform people who speak only one language ... irrelevant information to focus on important information. This means bilingual ... than one project at a time, said Judith Kroll, ...
... bigger role in the American health care system, argued ... conference of the American Association for the Advancement of ... health care costs depend on the policy context in ... Meltzer, Associate Professor of Medicine, in his presentation, "Policies ...
... leading lung cancer screening researchers, doctors and advocates. ... Early Lung Cancer Action Program (I-ELCAP) Screening Conferences. ... International Early Lung Cancer Action Program (I-ELCAP) and ... International Lung Cancer Consortium (ILCCO). This meeting ...
... (Feb 18, 2011) James C. Wittig, M.D., chief ... the John Theurer Cancer Center at Hackensack University Medical ... approaches to orthopedic oncology at the upcoming American Academy ... inventing some of the most-used best practices in limb-sparing ...
Cached Medicine News:Health News:Smoking During Head & Neck Cancer Therapy Tied to Poor Outcome 2Health News:Scientists bioengineer a protein to fight leukemia 2Health News:Cost-effectiveness research needs to be considered in developing new medical technology 2Health News:World's largest lung cancer screening conference to address benefits of CT scans 2Health News:John Theurer Cancer Center orthopedic oncologist shares new limb sparing surgical techniques 2Health News:John Theurer Cancer Center orthopedic oncologist shares new limb sparing surgical techniques 3Health News:John Theurer Cancer Center orthopedic oncologist shares new limb sparing surgical techniques 4Health News:John Theurer Cancer Center orthopedic oncologist shares new limb sparing surgical techniques 5Health News:John Theurer Cancer Center orthopedic oncologist shares new limb sparing surgical techniques 6Health News:John Theurer Cancer Center orthopedic oncologist shares new limb sparing surgical techniques 7
(Date:8/28/2014)...  Seres Health, a clinical-stage therapeutics company developing ... microbiome, announced today that Dr. David Cook ... Chief Scientific Officer, will be presenting at the ... (ICAAC). The presentation will highlight the scientific and ... bacterial spores derived from the human microbiome, and ...
(Date:8/28/2014)... PITTSBURGH , Aug. 28, 2014 /PRNewswire-iReach/ -- ... exhibiting at the 9 th Annual Global ... , September 8-9 th . The Global ... industry leaders in small molecule and biologic pharmaceutical ... address challenges that today,s manufacturers face, such as ...
(Date:8/28/2014)... Aug. 28, 2014 Reportlinker.com ... report is available in its catalogue: ... Asia-Pacific Markets to 2020 - Novel ... in Newly Diagnosed and Recurrent GBM ... Glioblastoma Multiforme Therapeutics ...
Breaking Medicine Technology:Seres Health to Present Clinical Findings at ICAAC 2014 Conference 2Gateway Analytical to Promote Particulate Identification Services at the 9th Annual Global Pharma Manufacturing Summit 2Gateway Analytical to Promote Particulate Identification Services at the 9th Annual Global Pharma Manufacturing Summit 3Glioblastoma Multiforme Therapeutics in Asia-Pacific Markets to 2020 - Novel Therapeutic Approaches Target High Unmet Need in Newly Diagnosed and Recurrent GBM 2Glioblastoma Multiforme Therapeutics in Asia-Pacific Markets to 2020 - Novel Therapeutic Approaches Target High Unmet Need in Newly Diagnosed and Recurrent GBM 3Glioblastoma Multiforme Therapeutics in Asia-Pacific Markets to 2020 - Novel Therapeutic Approaches Target High Unmet Need in Newly Diagnosed and Recurrent GBM 4Glioblastoma Multiforme Therapeutics in Asia-Pacific Markets to 2020 - Novel Therapeutic Approaches Target High Unmet Need in Newly Diagnosed and Recurrent GBM 5Glioblastoma Multiforme Therapeutics in Asia-Pacific Markets to 2020 - Novel Therapeutic Approaches Target High Unmet Need in Newly Diagnosed and Recurrent GBM 6Glioblastoma Multiforme Therapeutics in Asia-Pacific Markets to 2020 - Novel Therapeutic Approaches Target High Unmet Need in Newly Diagnosed and Recurrent GBM 7Glioblastoma Multiforme Therapeutics in Asia-Pacific Markets to 2020 - Novel Therapeutic Approaches Target High Unmet Need in Newly Diagnosed and Recurrent GBM 8Glioblastoma Multiforme Therapeutics in Asia-Pacific Markets to 2020 - Novel Therapeutic Approaches Target High Unmet Need in Newly Diagnosed and Recurrent GBM 9
... WILMINGTON, Del., Oct. 26 Next Intelligence Corporation ( ... today announced the expansion of its channel program for ... and system integrators (SI) to explore the growing health ... members sales leads, education on technical and selling aspects ...
... (Nasdaq: GTIV ), the nation,s largest provider of ... present at the Oppenheimer 21st Annual Healthcare Conference in New ... and the Credit Suisse 2010 Healthcare Conference in Phoenix, AZ ... 10, 2010. The presentations will be available to ...
Cached Medicine Technology:Next Intelligence Health Expands US Channel Program 2Gentiva® Health Services to Present at the Oppenheimer and Credit Suisse Healthcare Conferences 2Gentiva® Health Services to Present at the Oppenheimer and Credit Suisse Healthcare Conferences 3
The ZEPHIR Anterior Cervical Plate System is the lowest profile plate clinically available....
... The Philips Mx8000 IDT six-slice imaging ... incorporating leading technological innovations to maximize ... influencing departmental efficiency to delivering optimal ... the platform for multislice CT today ...
... Sharing the same proprietary Quantum detector technology ... a combination of speed and resolution not available ... to fit your clinical and budgetary needs, the ... a dedicated upgrade path to 16 slice productivity., ...
... TLIF Instruments are designed to facilitate disc ... bone graft during interbody fusion. The TLIF ... easy use during TLIF, for which they ... be used very effectively in PLIF and ...
Medicine Products: